Abstract Details

Title Measles, Rubella, and Varicella-Zoster Viral Antibodies and Clinical Prognosis After 20 Years in Persons with Multiple Sclerosis

Topic Autoimmune Neurology

Presentation(s) P1 - Poster Session 1 (12:00 PM-1:00 PM)

Poster/Presentation
Number 008

Objective Evaluate measles, rubella, and varicella-zoster viral antibodies (MRZ) reaction in a prospective cohort of persons with Multiple Sclerosis (pwMS) and its correlation with clinical prognosis 20 years after their initial baseline evaluation

Background In 1998 Reiber described the "MRZ-reaction" as an increased quantitative intrathecal synthesis of antibodies against measles (MV), rubella (RV), and varicella-zoster (VZ) viruses indicative of migration of B-lymphocytes subsets into central nervous system. This immunological phenomenon has been used as diagnostic marker of pwMS. To our knowledge has not been published studies about clinical evolution and prognosis related to MRZ status. Recently Epstein-Barr virus (EBV) initial infection has been related with immunological dysfunction in pwMS and possibly could be associated MRZ reaction with its clinical course.

Design/Methods A prospective cohort study of 77 pwMS recluted from 2002-2005 measuring MRZ-reaction in blood and CSF and clinical evaluation at baseline and 20 years after. This study was approved by Hospital´s Ethics Committee and an informed conset was obtained. The samples were immediately frozen at -80ºC until blind processed in parallel to determinate CSF albumin, IgG, Link and Reiber indexes. MV, RV, VZ specific antibodies indexes were calculated according to Reiber equation. Present clinical measurements (up to 30 April 2024) were compared to baseline: 2001 vs 2017 year McDonald diagnostic criteria, EDSS change, and disease-modifying therapy (DMT)

Results We found MRZ-reaction was an useful biologic diagnostic marker at baseline in this cohort of pwMS. We are analysing its clinical and prognostic correlation.

Conclusions MRZ-reaction is a biologic diagnostic marker of disease in pwMS. We expect higher levels of quantitive antibody titer are related with worse clinical evolution with more portion of pwMS with higher efficacy disease modifying treatments

Authors/Disclosures
Manuel Miguel Guerrero Fernandez, MD PRESENTER	Dr. Guerrero Fernandez has a non-compensated relationship as a AAN 2022 Seattle Meeting delegate with sanofi that is relevant to AAN interests or activities.
Antonio Sorlozano-Puerto	No disclosure on file
Francisco Barrero-Hernandez	No disclosure on file
Carmen Serrano Alvarez, Sr., MÉDICO	Mrs. Serrano Alvarez has nothing to disclose.
Raquel Piñar Morales	No disclosure on file
Jose Gutierrez Fernandez	Jose Gutierrez Fernandez has nothing to disclose.

��ɫ��

��ɫ��